1.50
Precedente Chiudi:
$1.49
Aprire:
$1.48
Volume 24 ore:
302.57K
Relative Volume:
1.13
Capitalizzazione di mercato:
$32.39M
Reddito:
-
Utile/perdita netta:
$-8.32M
Rapporto P/E:
-3.1146
EPS:
-0.4816
Flusso di cassa netto:
$-7.43M
1 W Prestazione:
+2.74%
1M Prestazione:
+52.64%
6M Prestazione:
+0.00%
1 anno Prestazione:
+17.19%
NanoViricides Inc Stock (NNVC) Company Profile
Nome
NanoViricides Inc
Settore
Industria
Telefono
203-937-6137
Indirizzo
1 Controls Drive, Shelton, CT
Compare NNVC vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
NNVC
NanoViricides Inc
|
1.50 | 32.18M | 0 | -8.32M | -7.43M | -0.4816 |
|
VRTX
Vertex Pharmaceuticals Inc
|
448.29 | 110.45B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
723.41 | 74.73B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
812.81 | 50.58B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
292.03 | 38.03B | 4.29B | 577.22M | 641.34M | 4.2086 |
|
ONC
Beone Medicines Ltd Adr
|
315.07 | 32.24B | 5.76B | 514.49M | 1.10B | 4.4813 |
NanoViricides Inc Stock (NNVC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-16 | Iniziato | Alliance Global Partners | Buy |
| 2015-02-11 | Iniziato | Midtown Partners | Strong Buy |
NanoViricides Inc Borsa (NNVC) Ultime notizie
NNVC stock up 17% today: What’s driving the rally? - MSN
TradingKey - TradingKey
NNVC Stock Up 17% Today: What’s Driving The Rally? - Stocktwits
NanoViricides Highlights Broad-Spectrum Antiviral Candidate After Andes Hantavirus Incident on Cruise Ship - citybuzz -
Small cap wrap: Gunnison Copper, Graphene Manufacturing Group, NanoViricides… - Proactive financial news
NanoViricides says hantavirus incident highlights need for antiviral drugs - TipRanks
Does the Recent Hantavirus Outbreak Highlight a Critical Gap for NanoViricides' NV-387 - Kavout
Cruise ship hantavirus deaths spark call for broad-spectrum antiviral drugs - Stock Titan
NanoViricides says Phase I antiviral drug could address gap exposed by hantavirus cruise ship outbreak - Proactive financial news
What NanoViricides (NNVC) bond yields suggest about risk | Q1 2026: Earnings Beat EstimatesWall Street Picks - newser.com
NNVC (NanoViricides) shares surge 9% as EPS beat targets by 23%, defying analyst expectations despite ongoing losses.Trading Community - newser.com
NanoViricides to Present at D. Boral Capital Global Conference as Lead Drug Candidate Advances Toward Phase II Trials - citybuzz -
NanoViricides to Present at D. Boral Capital Global Conference - HarianBasis.co
NanoViricides (NNVC) Secures FDA Orphan Drug Status for NV-387 Measles Treatment - Insider Monkey
NanoViricides to Participate at D. Boral Capital Global Conference in NYC - Yahoo Finance
NanoViricides to present at D. Boral Capital Global Conference May 7 in NYC - Pluang
NanoViricides, Inc. Announces Participation in the D. Boral Capital Global Conference - Oil & Gas 360
NanoViricides to attend D Boral Capital Conference - Proactive financial news
NanoViricides management offers investor meetings in New York May 7 - Stock Titan
NanoViricides’ Measles Treatment Granted Orphan Drug Designation by FDA - Yahoo Finance
NanoViricides’ NV-387 Receives FDA Orphan Drug Designation for Measles Treatment - MEXC Exchange
NanoViricdes Surges on Winning ODD Status - Baystreet.ca
NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA - Lelezard
NanoViricides antiviral drug NV-387 wins FDA Orphan Drug Designation for measles treatment - Yahoo Finance
FDA orphan tag gives NanoViricides measles drug tax credits, fee waiver - Stock Titan
NNVC Stock Price, Quote & Chart | NANOVIRICIDES INC (NYSEARCA:NNVC) - ChartMill
Is NanoViricides (NNVC) stock forming a clear pattern | Q1 2026: Profit Exceeds ViewsShared Buy Zones - newser.com
NNVC Forecast, Price Target & Analyst Ratings | NANOVIRICIDES INC (NYSEARCA:NNVC) - ChartMill
NNVC (NanoViricides Inc.) beats Q1 2026 EPS estimates by 23 percent, but posts a slight post-earnings share decline. - Cổng thông tin điện tử tỉnh Tây Ninh
NNVC NanoViricides exceeds Q1 2026 EPS estimates by 23 percent, but shares drop 4.89 percent on zero quarterly revenue.Trading Community - UBND thành phố Hải Phòng
NanoViricides says NV-387 could address measles outbreaks as cases rise globally - Yahoo Finance
Deadly Measles Cases Accentuate the Need for a - One News Page
Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides - ACCESS Newswire
NanoViricides to Present at the 15th Annual BIO-CEO Conference in NYC Tomorrow - AOL.com
Profit Recap: Can NanoViricides Inc continue delivering strong returns2026 Volatility Report & AI Enhanced Market Trend Forecasts - baoquankhu1.vn
NanoViricides seeks FDA’s rare pediatric disease designation for antiviral candidate NV-387ICYMI - Proactive financial news
Macro Review: Should I hold or sell GMREPRA now2026 Spike Watch & Community Consensus Stock Picks - baoquankhu1.vn
Weekly Earnings: Is NanoViricides Inc subject to activist investor interestTake Profit & Real-Time Buy Signal Notifications - baoquankhu1.vn
Aug Summary: Is NanoViricides Inc undervalued by DCF analysisWeekly Gains Report & Stock Timing and Entry Methods - baoquankhu1.vn
NanoViricides files for Rare Pediatric Disease Designation for Measles Drug - Proactive financial news
Growth Value: Can NanoViricides Inc stock double in the next year2026 Technical Overview & Short-Term Trading Alerts - baoquankhu1.vn
Can NanoViricides (NNVC) Stock Go Higher | Price at $1.15, Up 6.48%Trade Entry - newser.com
NanoViricides Inc Azioni (NNVC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):